Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
9
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
9
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
9
×
new york top stories
novartis
9
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
9
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
gene therapy
ipo
cancer
deals
fda
medicare
startups
abbvie
alzheimer's disease
cancer immunotherapy
celgene
What
bio
roundup
ipo
drug
new
acquisitions
biogen
ceo
companies
covid
crispr
fda
gene
healthcare
medicines
moves
news
patients
price
remains
talk
years
activity
albert
allogene
alzheimer’s
america
announced
approval
approvals
august
becker
biggest
billions
biogen’s
biopharmaceutical
biotech
bourla
busy
cancer
Language
unset
unknown
Current search:
novartis
×
biogen
×
" detroit top stories "
×
" san francisco top stories "
×
" new york blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More